1. Peroxisome Proliferator-activated Receptor-γ As A Novel and Promising Target For Treating Cancer Via Regulation of Inflammation: A Brief Review
- Author
-
S. Yuvaraj and B. R. Prashantha Kumar
- Subjects
Male ,Peroxisome proliferator-activated receptor ,Inflammation ,Ligands ,medicine.disease_cause ,Neoplasms ,Drug Discovery ,Tumor Microenvironment ,medicine ,Animals ,Transcription factor ,Pharmacology ,chemistry.chemical_classification ,Tumor microenvironment ,business.industry ,Cancer ,General Medicine ,medicine.disease ,PPAR gamma ,chemistry ,Nuclear receptor ,Cancer cell ,Cancer research ,Inflammation Mediators ,medicine.symptom ,business ,Carcinogenesis ,Transcription Factors - Abstract
Peroxisome proliferator activated receptors (PPARs) are a group of nuclear receptors and the ligand-activated intracellular transcription factors that are known to play a key role in physiological processes such as cell metabolism, proliferation, differentiation, tissue remodeling, inflammation, and atherosclerosis. However, in the past two decades, many reports claim that PPARs also play an imperious role as a tumor suppressor. PPAR- gamma (PPARγ), one of the best-known from the family of PPARs, is known to express in colon, breast, bladder, lung, and prostate cancer cells. Its function in tumour cells includes the modulation of several pathways involved in multiplication and apoptosis. The ligands of PPARγ act by PPARγ dependent as well as independent pathways and are also found to regulate different inflammatory mediators and transcription factors in systemic inflammation and in tumor microenvironment. Both synthetic and natural ligands that are known to activate PPARγ, suppress the tumor cell growth and multiplication through the regulation of inflammatory pathways, as found out from different functional assays and animal studies. Cancer and inflammation are interconnected processes that are now being targeted to achieve tumor suppression by decreasing the risks and burden posed by cancer cells. Therefore, PPARγ can serve as a promising target for development of clinical drug molecule attenuating the proliferation of cancer cells. In this perspective, this mini review highlights the PPARγ as a potential target for drug development aiming for anti-inflammatory and thereby suppressing tumors.
- Published
- 2022